Roche: Currency Headwinds Are Masking Strong Growth Trends
Roche's key products like Vabysmo, Ocrevus, and Phesgo are performing well. Read why RHHBY stock looks well positioned to ...
FiercePharma24d
Jazz's almost-withdrawn lung cancer drug Zepzelca extends life on top of Roche's Tecentriq
Zepzelca, used in combination with Roche’s Tecentriq, outperformed Tecentriq alone when used as a first-line maintenance treatment in ES-SCLC following induction therapy with Tecentriq and chemo ...
Pharmabiz1d
Roche to present more than 40 abstracts across nine blood disorders at the 66th ASH meeting
Roche announced that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held 7-10 December 2024 in San ...
Business Insider29d
Tempest Inks Deal With Roche To Support Advancement Of Amezalpat Combination Therapy
announced Thursday an agreement with Roche Group (RHHBY.PK) to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq) and bevacizumab, the current standard of ...
Halozyme: Looking For More Growth Following Record Q3 Earnings
Halozyme's Q3 earnings exceeded expectations, with a $1.27 EPS and 34% YoY revenue growth, driven by ENHANZE tech and strong ...
Taiwan News3d
Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024
Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes #469 oral presentation Session: 626.
Yahoo Finance7d
Roche Holding AG (RHHBY)
16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while ...
Business Insider29d
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated ...
Stockhouse29d
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated ...